HPC2/ELAC2 Gene and Prostate Cancer Risk
Author Information
Author(s): Meitz J C, Edwards S M, Easton D F, Murkin A, Ardern-Jones A, Jackson R A, Williams S, Dearnaley D P, Stratton M R, Houlston R S, Eeles R A
Primary Institution: Institute of Cancer Research
Hypothesis
Is there an association between HPC2/ELAC2 polymorphisms and prostate cancer risk?
Conclusion
The study found no significant association between the Thr541 variant of the HPC2/ELAC2 gene and prostate cancer risk.
Supporting Evidence
- The study included a large sample size of 901 participants.
- Results showed no significant difference in genotype frequencies between cases and controls.
- The odds ratio for the Thr541 variant was 1.41, indicating a weak association.
- Confidence intervals were wide, suggesting uncertainty in the estimates.
- Previous studies reported conflicting results regarding the association of HPC2/ELAC2 with prostate cancer.
Takeaway
Researchers looked at a gene to see if it makes people more likely to get prostate cancer, but they didn't find a strong link.
Methodology
The study genotyped 432 prostate cancer patients and 469 controls, analyzing the frequencies of specific gene variants.
Limitations
The study excluded non-Caucasian patients and focused only on specific age groups.
Participant Demographics
The study included 432 prostate cancer patients, with 262 diagnosed at age 55 or younger.
Statistical Information
P-Value
0.13
Confidence Interval
95% CI 0.79–2.50
Statistical Significance
p=0.13
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website